EarningsQ2 2026 Earnings Report
MX:RVTY Q2 2026 EPS Results
Actual EPS$25.48
Consensus EPS$21.94
Beat/MissBeat by +$3.54
One Year Ago EPS$21.33
MX:RVTY Q2 2026 Revenue Results
Actual Revenue$13.19B
Expected Revenue$12.70B
Beat/MissBeat by +$483.12M
YoY Revenue Growth+1.31%
Earnings Announcement Details
QuarterQ2 2026
Date08/04/2026
TimeBefore Open
Conference CallTuesday, August 4, 2026
MX:RVTY Upcoming Earnings
Revvity's next earnings date is estimated for November 3, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:RVTY Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented a generally positive operational and financial picture: revenue and EPS beat with upgraded full-year guidance, strong Diagnostics performance, accelerating high-content instrument orders and robust cash flow and balance sheet improvements. Key near-term weaknesses include a sizable decline in Signals software revenue this quarter, some production/timing constraints that shifted instrument revenue into Q3, and portions of the quarter's outperformance tied to one-time tariff refunds and tax timing. Management plans reinvestments of a portion of one-time benefits while highlighting new software capabilities and AI-driven demand as multi-year growth drivers—though the AI opportunity is still early and not fully quantifiable.Company Guidance
Top-line and Organic Growth Beat
Q2 pro forma revenue of $711M with 3% pro forma organic growth, slightly above the high end of guidance; full-year organic growth guidance raised to 4%–5% (from 3%–4%).
Adjusted EPS and Updated Full-Year Outlook
Q2 pro forma adjusted EPS of $1.41, above guidance; full-year pro forma adjusted EPS raised to $5.30–$5.40 (up $0.10).
Strong Margin and Operational Performance
Q2 pro forma adjusted operating margin of 29.3% (vs. prior 27% outlook); full-year pro forma adjusted operating margin raised to 28.7% (up 30 basis points).
Diagnostics Segment Strength
Diagnostics revenue $352M, organic growth +11% in Q2; reproductive health grew mid-teens and immunodiagnostics (ex-China) accelerated to high-single-digit growth; Genomics England contribution performing well (~$25M expected full-year).
High-Content Screening Momentum
High-content screening instruments, including the new Opera Phenix OptIQ, delivered double-digit year-over-year order growth; instrument backlog exiting Q2 at strongest level in 3–4 years, with order velocity outpacing near-term capacity.
Signals Software Fundamental Strength
Signals APV growing in the double digits and ARR in the mid-20s; new product rollouts (BioDesign commercial, Synthetica beta, Signals AI, Anthropic connector, LabGistics) position software for a return to strong double-digit growth in H2 despite Q2 comps.
Cash Flow, Balance Sheet and Capital Actions
Q2 free cash flow $184M with adjusted net income conversion of 117%; YTD free cash flow ≈$300M (108% conversion); retired EUR 500M note, pro forma net debt/EBITDA 2.5x and expecting gross leverage below 3x and net leverage near 2x by year-end; 100% fixed-rate debt with 2.3% weighted avg rate.
Acquisition Integration and Revenue Contribution
ACD/Labs software integration progressing faster than anticipated; ACD/Labs expected to contribute ~75 basis points to full-year revenue growth.
MX:RVTY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed